| scholarly article | Q13442814 |
| P50 | author | Ralph H. Hruban | Q21063634 |
| Antonio Pea | Q56816595 | ||
| P2093 | author name string | Laura D Wood | |
| P2860 | cites work | Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription | Q22001458 |
| Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling | Q24290996 | ||
| Menin, a gene product responsible for multiple endocrine neoplasia type 1, interacts with the putative tumor metastasis suppressor nm23 | Q24291124 | ||
| The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation | Q24291618 | ||
| Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres | Q24292850 | ||
| Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 | ||
| Menin associates with FANCD2, a protein involved in repair of DNA damage | Q24310300 | ||
| Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors | Q24337658 | ||
| A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity | Q24514960 | ||
| Molecular genetics of neurofibromatosis type 1 (NF1) | Q24518449 | ||
| mTOR signaling in growth control and disease | Q24634174 | ||
| Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies | Q24647838 | ||
| Zollinger-Ellison syndrome associated with neurofibromatosis type 1: a case report | Q24815486 | ||
| A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor | Q27003534 | ||
| Lanreotide in metastatic enteropancreatic neuroendocrine tumors | Q28243728 | ||
| Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function | Q28254826 | ||
| Distinct factors control histone variant H3.3 localization at specific genomic regions | Q28275277 | ||
| Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases | Q28290384 | ||
| DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors | Q28303693 | ||
| Positional cloning of the gene for multiple endocrine neoplasia-type 1 | Q28307577 | ||
| Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c | Q28506197 | ||
| Menin induces apoptosis in murine embryonic fibroblasts | Q28589504 | ||
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
| Identification of the von Hippel-Lindau disease tumor suppressor gene | Q29618644 | ||
| Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome | Q30815312 | ||
| Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma | Q48100816 | ||
| Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. | Q50761477 | ||
| Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. | Q50794017 | ||
| Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients. | Q53272124 | ||
| Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. | Q53359692 | ||
| Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological, and genetic features. | Q53407685 | ||
| [Neurofibromatosis von Recklinghausen type 1 (NF1) - clinical picture and molecular-genetics diagnostic]. | Q54291303 | ||
| High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. | Q54469598 | ||
| Pancreatic endocrine tumors are a rare manifestation of the neurofibromatosis type 1 phenotype: molecular analysis of a malignant insulinoma in a NF-1 patient. | Q54590983 | ||
| Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. | Q55472960 | ||
| Somatostatin receptors | Q58448612 | ||
| Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival | Q59647330 | ||
| Pancreatic involvement in von Hippel–Lindau disease | Q62929393 | ||
| Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma | Q67485775 | ||
| Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome | Q68084123 | ||
| Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases | Q69855897 | ||
| [Recklinghausen's disease with digestive localizations associated with gastric acid hypersecretion suggesting Zollinger-Ellison syndrome] | Q69940608 | ||
| Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma | Q72866285 | ||
| Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance | Q73013904 | ||
| Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease | Q73292303 | ||
| Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors | Q73428887 | ||
| Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9Q34 is an early event in insulinomas | Q74114518 | ||
| Expression of vascular endothelial growth factor in digestive neuroendocrine tumours | Q74447035 | ||
| INSULINOMA AND MULTIPLE NEUROFIBROMATOSIS: REPORT OF A CASE | Q76801912 | ||
| Multiple endocrine neoplasia type 1: clinical and genetic topics | Q77292736 | ||
| Genomic imbalances in the progression of endocrine pancreatic tumors | Q77361239 | ||
| Chromosome 22q in pancreatic endocrine tumors: identification of a homozygous deletion and potential prognostic associations of allelic deletions | Q78346047 | ||
| An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors | Q79378332 | ||
| Molecular parameters associated with insulinoma progression: chromosomal instability versus p53 and CK19 status | Q79379768 | ||
| Chromosomal instability predicts metastatic disease in patients with insulinomas | Q81832529 | ||
| HIRA and Daxx Constitute Two Independent Histone H3.3-Containing Predeposition Complexes | Q82295373 | ||
| [Type I neurofibromatosis, pheochromocytoma and somatostatinoma of the ampulla. Literature review] | Q82323609 | ||
| Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 | Q83300174 | ||
| Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy | Q83761732 | ||
| Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors | Q86061058 | ||
| The genetics of neuroendocrine tumors | Q86078968 | ||
| Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas | Q31030383 | ||
| Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features | Q33258694 | ||
| Endocrine neoplasms of the pancreas: pathologic and genetic features | Q33414797 | ||
| PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors | Q33767655 | ||
| The NF1 tumor suppressor critically regulates TSC2 and mTOR. | Q33841600 | ||
| Multiple endocrine neoplasia type 1. | Q33871564 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors | Q34010378 | ||
| Sunitinib malate for the treatment of pancreatic neuroendocrine tumors | Q34163515 | ||
| Altered telomeres in tumors with ATRX and DAXX mutations | Q34196696 | ||
| ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors | Q34248466 | ||
| Everolimus for advanced pancreatic neuroendocrine tumors. | Q34399809 | ||
| The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. | Q34464857 | ||
| Malignant endocrine tumor of the pancreas associated with von Recklinghausen's disease | Q34514963 | ||
| Hereditary pancreatic endocrine tumours. | Q34549251 | ||
| Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. | Q34573905 | ||
| Population-based study of islet cell carcinoma | Q34693373 | ||
| Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients | Q34729926 | ||
| Neurofibromatosis, phaeochromocytoma, and somatostatinoma | Q34766709 | ||
| Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway | Q34887795 | ||
| Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial | Q34965132 | ||
| Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors | Q35563828 | ||
| PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR | Q35613890 | ||
| Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinica | Q35640506 | ||
| Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors | Q35681234 | ||
| Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis | Q35753186 | ||
| Chromosomal alterations detected by comparative genomic hybridization in nonfunctioning endocrine pancreatic tumors | Q35978878 | ||
| Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas? | Q36300517 | ||
| First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas | Q36335402 | ||
| Von Hippel-Lindau disease and endocrine tumour susceptibility | Q36489892 | ||
| Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors | Q36541359 | ||
| Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression | Q36615803 | ||
| Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin | Q36620016 | ||
| Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. | Q36793415 | ||
| Targeting ALT: the role of alternative lengthening of telomeres in pathogenesis and prevention of cancer | Q36969406 | ||
| Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study | Q37121673 | ||
| Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib | Q37130616 | ||
| Tuberous sclerosis: unusual associations in four cases | Q37180044 | ||
| One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States | Q37195528 | ||
| Chromosomal instability is more frequent in metastasized than in non-metastasized pulmonary carcinoids but is not a reliable predictor of metastatic potential | Q37241681 | ||
| Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion | Q37255122 | ||
| Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival | Q37326199 | ||
| An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes | Q37459597 | ||
| Periampullary and duodenal neoplasms in neurofibromatosis type 1: two cases and an updated 20-year review of the literature yielding 76 cases | Q37714407 | ||
| Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy | Q37773478 | ||
| The epidemiology of gastroenteropancreatic neuroendocrine tumors. | Q37846915 | ||
| Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study | Q37961390 | ||
| Neuroendocrine tumors of the pancreas: current concepts and controversies. | Q38178882 | ||
| Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. | Q38468233 | ||
| Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives. | Q38527936 | ||
| Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines. | Q38862463 | ||
| Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material | Q39316548 | ||
| Menin represses JunD transcriptional activity in protein kinase C theta-mediated Nur77 expression | Q40355558 | ||
| The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis | Q40359760 | ||
| Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma | Q40593218 | ||
| bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. | Q42505657 | ||
| Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group | Q43286770 | ||
| VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors | Q43290089 | ||
| Treatment with cisplatin and etoposide in patients with neuroendocrine tumors | Q43747293 | ||
| Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines | Q43864431 | ||
| Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study | Q43905778 | ||
| In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial | Q43966911 | ||
| Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients | Q44301609 | ||
| MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases | Q44303888 | ||
| Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas | Q44582807 | ||
| Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. | Q44646733 | ||
| Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. | Q44732861 | ||
| The pharmacology of mTOR inhibition | Q46041824 | ||
| Deletion mapping of endocrine tumors localizes a second tumor suppressor gene on chromosome band 11q13. | Q46229550 | ||
| Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor | Q46562102 | ||
| Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival | Q46619794 | ||
| Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors | Q46900223 | ||
| Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial. | Q48057935 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 1407-1419 | |
| P577 | publication date | 2015-09-28 | |
| P1433 | published in | Expert Review of Gastroenterology & Hepatology | Q15733730 |
| P1476 | title | Genetics of pancreatic neuroendocrine tumors: implications for the clinic | |
| P478 | volume | 9 |
| Q47170689 | Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel |
| Q49957735 | Current and emerging therapies for PNETs in patients with or without MEN1. |
| Q98612725 | Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations |
| Q26748615 | Surgical and molecular pathology of pancreatic neoplasms |
| Q91595896 | Zebrafish patient avatars in cancer biology and precision cancer therapy |
Search more.